The optimal venous access for the chemotherapy in children

Rykov M.Iu.; Buĭdenok Iu.V.

doi:https://doi.org/

Rykov M.Iu.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Buĭdenok Iu.V.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

The optimal venous access for the chemotherapy in children

Authors:

Rykov M.Iu., Buĭdenok Iu.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2012;(9): 60‑63

Read: 925 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rykov MIu, Buĭdenok IuV. The optimal venous access for the chemotherapy in children. Pirogov Russian Journal of Surgery. 2012;(9):60‑63. (In Russ.)

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Primary outcomes after major anatomical liver resections in infants at the National Children’s Medical Center. Pirogov Russian Journal of Surgery. 2025;(4):86-94

Oral cavity cancer epidemiology in men and women in the Siberian Federal District. Russian Journal of Preventive Medicine. 2024;(11):46-53

Cost of supportive cancer care in the Russian Federation. Part 2. Medical Technologies. Assessment and Choice. 2024;(4):63-73

History creates man, and man creates history. On the 125th anniversary of the P.A. Herzen Moscow Oncology Research Institute. P.A. Herzen Journal of Oncology. 2024;(6):5-11

Use of a new tetrapeptide analgesic at the stages of antitumor therapy. P.A. Herzen Journal of Oncology. 2024;(6):23-32

Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in antitumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143

Approaches to the digitization of clinical guidelines. Medical Technologies. Assessment and Choice. 2025;(2):39-47

Dynamics of the main indicators of medical care to the population of the Russian Federation for the period 1993—2023 in the “Oncology” profile. P.A. Herzen Journal of Oncology. 2025;(3):71-77

Use of HIFU therapy in combination with monochemotherapy in a patient with locally advanced adenogenic pancreatic cancer and impaired functional status. P.A. Herzen Journal of Oncology. 2025;(3):83-88

Evaluation of the skeletal muscle index in predicting toxic complications of antitumor drug therapy in patients with gastric cancer. P.A. Herzen Journal of Oncology. 2025;(4):29-36

Abstract:

The optimal choice for the long-term venous access for children is a full implanted venous port systems. We own the experience of 87 port implantations to children aged from 6 months to 17 years with various oncological disease. The experience was successful in all cases but one, where the septic inflammation of the subcutaneous pocket developed.

Keywords:

oncology

chemotherapy

venous port-systems

venous acces

Authors:

Rykov M.Iu.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Buĭdenok Iu.V.

Nauchno-issledovatel'skiĭ institut detskoĭ onkologii i gematologii Rossiĭskogo onkologicheskogo nauchnogo tsentra im. N.N. Blokhina RAMN, Moskva

Close metadata

References:

Buidenok Yu.V., Meshcheryakov A.A. Implantiruemye port-sistemy venoznogo dostupa v onkologii. Vestn intens terapii 2004; 3: 3-8.
Galt'eri I., Deppe I., Siperli M., Tomson D. Kateterizatsiya podklyuchichnoi veny: ul'trazvukovoi kontrol' pozvolyaet menee opytnym vracham dobit'sya luchshikh rezul'tatov. Vestn intens terapii 2006; 4: 24-30.
Egiev V.N., Shchetinin V.V., Trofimenko Yu.G. Polnost'yu implantiruemye sistemy v meditsine. M: Medpraktika-M 2004; 60.
Sukhorukov V.P., Berdikyan A.S., Epshtein S.L. Punktsiya i kateterizatsiya ven. Traditsionnye i novye tekhnologii. Posobie dlya vrachei. Sankt-Peterburgskoe meditsinskoe izdatel'stvo 2001; 55.
Blenkharn J.I. In vitro antibacterial activity of noxythiolin and taurolidine. J Pharm Pharmacol 1990; 42: 589-590.
Browne M.K., Leslie G.B., Pfirrmann R.W. Taurolin, a new chemothera peutic agent. J Appl Bacteriol 1976; 41: 363-368.
Browne M.K. Pharmacological and clinical studies with Taurolin®. In: Bruckner W.L., Pfirrman R.W.R., editors. Proceedings of the International Taurolin Symposium 1985.
Calabresi P., Goulette F.A., Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001; 61: 6816-6821.